Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling